Clinical study of traxanox sodium, an antiallergic drug, in the treatment of perennial nasal allergy.

概要

論文の詳細を見る
Traxanox sodium was given in a dose of 360 mg/day to 19 patients with nasal allergy. Improvement was "moderate" or better in 65% and "slightly" or better in 84%. The safety score was "safe" or "almost safe" in 95%.Its clinical usefulness was rated "moderately useful" or more in 68% and in "slightly useful" or more in 84%. Improvement in nasal symptoms was 76%, for sneezing attacks, 76%, for nasal discharges and 58%, for nasal obstruction. Adverse reaction were observed in 3 patients.It is concluded that the oral administration of traxanox sodium in a dose of 360 mg/day is usefull for patients with nasal allergy.
耳鼻咽喉科臨床学会の論文